MilliporeSigma Introduces Mobius® MyWay Portfolio for Customized Single-use Assemblies

- New portfolio provides shorter lead times for more rapid biomanufacturing

- Optimizes balance of delivery speed and customization

BILLERICA, Mass., March 21, 2017 /CNW/ -- MilliporeSigma, a leader in single-use technology, today launched an industry first—the Mobius^® MyWay portfolio, a program that allows more flexibility, better supply predictability and shorter lead times for more efficient and safer drug manufacture.

"We have the industry's only comprehensive single-use solution, giving customers three different ways to create customizable assemblies," said Andrew Bulpin, Head of Process Solutions Strategic Marketing & Innovation, MilliporeSigma. "This is critical to customers from contract manufacturing organizations to big pharma, whose biggest challenge is getting custom assemblies with fast, reliable lead times for quicker turnarounds and more rapid biomanufacturing."

For commercial manufacturers, MilliporeSigma's Mobius^® MyWay portfolio helps minimize schedule disruptions and delays. Pilot plants benefit from faster assembly design and delivery in order to adjust to new and evolving needs in real-time. Contract manufacturing organizations benefit from more reliable lead times allowing for better planning, which helps ensure on-time product delivery.

MilliporeSigma's portfolio offers a choice of off-the-shelf and configured-to-order assemblies, as well as fully customizable configurations. Assemblies available as part of the Mobius^® MyWay portfolio are used for safe and effective fluid management across upstream and downstream processes, from routine buffer and media prep, to critical premium aseptic process and final drug manufacturing.

Assemblies are segmented into three categories, each offering a different level of configuration flexibility:

• Mobius^® Stock offers on-demand solutions ready to ship in 24 hours.
• Mobius^® Select offers an optimal balance of speed and configurability of custom assemblies from an optimized component library with an agile 6-week lead time.
• Mobius^® Choice offers highly customized solutions from our expansive component library, shipped in standard lead times.

Among the assemblies included in the Mobius^® MyWay portfolio are Mobius^® MIX systems and bags up to 1,000 liters; holding and transport vessels up to 3,500 liters; Lynx^® CDR sterile connectors and single-use final formulation, filtration and final fill assemblies.

All Merck KGaA, Darmstadt, Germany news releases are distributed by email at the same time they become available on the EMD Group website. In case you are a resident of the U.S. or Canada please go to www.emdgroup.com/subscribe to register again for your online subscription of this service as our newly introduced geo-targeting requires new links in the email. You may later change your selection or discontinue this service.

About the Life Science Business of Merck KGaA, Darmstadt, Germany

The life science business of Merck KGaA, Darmstadt, Germany, which operates as MilliporeSigma in the U.S. and Canada, has 19,000 employees and 65 manufacturing sites worldwide, with a portfolio of more than 300,000 products enabling scientific discovery. Udit Batra is the global chief executive officer of MilliporeSigma.

Merck KGaA, Darmstadt, Germany completed its $17 billion acquisition of Sigma-Aldrich in November 2015, creating a leader in the $125 billion global life science industry.

Merck KGaA, Darmstadt, Germany is a leading company for innovative and top-quality high-tech products in healthcare, life science and performance materials. The company has six businesses – Biopharmaceuticals, Consumer Health, Allergopharma, Biosimilars, Life Science and Performance Materials – and generated sales of €12.85 billion in 2015. Around 50,000 employees work in 66 countries to improve the quality of life for patients, to foster the success of customers and to help meet global challenges.

Merck KGaA, Darmstadt, Germany is the world's oldest pharmaceutical and chemical company – since 1668, the company has stood for innovation, business success and responsible entrepreneurship. Holding an approximately 70 percent interest, the founding family remains the majority owner of the company to this day. The company holds the global rights to the name and the trademark "Merck" internationally except for the United States and Canada, where the company operates as EMD Serono, MilliporeSigma and EMD Performance Materials.

SOURCE MilliporeSigma

For further information: Karen Tiano [phone]